Kim Papp’s Post

🌟 Exploring Midermcol Gel: A Deep Dive into Its Pharmacodynamics, Gentamicin Potency, and Clinical Applications 🌟 💥 Nvron Life Science continues to push the boundaries of innovation with Midermcol Gel, a cutting-edge dermatological solution that merges advanced pharmacodynamics with the potent antibacterial properties of Gentamicin. This formulation offers clinicians a powerful tool in the treatment of various skin conditions. Our latest treatise delves into the intricate mechanisms of action, exploring how Midermcol Gel works at the molecular level, its efficacy in clinical settings, and its implications for patient care. 🤝 Join us as we unpack the science behind this groundbreaking gel and its potential to revolutionize skin care treatment protocols. #NvronLifeScience #MidermcolGel #Pharmacodynamics #Gentamicin #ClinicalResearch #Dermatology #InnovationInMedicine #SkinCareSolutions #HealthcareExcellence #PharmaIndustry #MedicalAdvances

🚨 New data at #FallClinical: Lebrikizumab-lbkz (Ebyglyss) treatment of moderate-to-severe #AtopicDermatitis led to improvements in patients’ skin (including hands and face) and itch among those who were previously treated with dupilumab. These findings were announced by Elil Lilly & Company and authored by such investigators as Linda Stein Gold, MD, of Henry Ford Health. To learn more, check out our summary here: https://lnkd.in/g6dnUyCF #dermatology #lebrikizumab #eczema

I'm pleased to announce the publication of our latest case report, "Dapsone Induced Hypersensitivity Syndrome (DHS) in Case of Leprosy," in the International Journal of Biology, Pharmacy, and Allied Sciences (IJBPA). This report explores a case of a 38-year-old female patient who developed DHS, a severe adverse reaction characterized by fever, skin eruptions, and internal organ involvement, during Dapsone therapy for leprosy. The study highlights the importance of timely diagnosis and monitoring to mitigate adverse events and improve patient outcomes. #Dapsone #HypersensitivitySyndrome #Leprosy #ClinicalResearch #Dermatology #Pharmacology #IJBPA #PatientSafety #AdverseDrugReaction 4o

Eli Lilly and Company announced that the FDA has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in patients 12 years and older who are not well-controlled with topical therapies.    The approval is based on the ADvocate and ADhere studies, offering a new treatment option for those with hard-to-control eczema symptoms. EBGLYSS reduces inflammation and symptoms like dry, itchy skin. Clinical trials showed 38% of patients achieved clearer skin by Week 16, with many experiencing itch relief as early as two weeks.    Read more: https://lnkd.in/eEbQXZFD   #Dermatology #AtopicDermatitis #Eczema

Thrilled to share our latest publication in the International Wound Journal! Our work, "A review on toxic epidermal necrolysis‐like superficial wound lesions: issues and challenges in 10 clinical entities", dives into the complexities of diagnosing and managing toxic epidermal necrolysis (TEN) and TEN-like conditions. In this work, we explore ten distinct clinical entities that mimic TEN, providing insights into their clinical pattern, pathophysiology, diagnosis, and treatment. This work wouldn’t have been possible without the incredible support and collaboration of our guiding professor, Dr. Abtahi-Naeini and my esteemed colleagues Ali Emamjomeh and Fereshte Rastegarnasab. We hope this article contributes to improving diagnostic accuracy and patient care in these conditions. I’ve attached the full article to this post. I encourage you to read it and share your thoughts—I’d love to hear your feedback! #MedicalResearch #Dermatology #SystematicReview #ToxicEpidermalNecrolysis #Healthcare

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both primary and all key secondary goals. GALDERMA R&D global head Baldo Scassellati Sforzolini said: “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent US Food and Drug Administration approval for the treatment of adults with PN" Click here for the full article - https://lnkd.in/dCT3sRJx #clinicaltrials #dermatology

Things are happening so fast in the dermatology space, it’s almost hard to keep up. Amazing innovation is happening for biologics in atopic dermatitis. In the current playbook, dupilumab and tralokinumab have both been approved to treat atopic dermatitis in the United States, with dupilumab also being approved to treat patients with prurigo nodularis. Lebrikizumab and nemolizumab are also approved to treat atopic dermatitis in other countries. According to the National Eczema Association, 25 new biologics are in development for treatment of atopic dermatitis. Read more: https://bit.ly/3y7nGwa To learn more about biologics, plus other cutting-edge therapies for atopic dermatitis, alopecia areata, and vitiligo, sign up for the Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conferences, taking place June 8-10, in Chicago, Illinois. Don’t miss out! Register: https://bit.ly/3xcuWGG #atopicdermatitis #alopeciaareata #vitiligo #dermatology #dermatologists #chicago #physicians #registerednurses #physiciansassistant #nursepractitioner #medicalstudents #medicalresidents

ACELYRIN, INC. announced positive top-line results from its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA). Izokibep met its primary endpoint of ACR50 at week 16 by showing a high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. Izokibep also showed to be well-tolerated with a favorable safety profile which remains consistent with the IL-17A class. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe HS, PsA, and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA). #Rheumatology #Dermatology #PsoriaticArthritis #PsA #HidradenitisSuppurativa #HS #ACELYRIN #izokibep Read more: https://lnkd.in/eet-y-hR

Dr Ashley O'Toole and Dr Melinda Gooderham in Vienna, Austria 🇦🇹 with a group of Canadian delegates to discuss atopic dermatitis, prurigo nodularis and Type 2 inflammation with global colleagues. 👍 This was an excellent opportunity for them to brush up on their presentation skills and exchange insights and their clinical trial experience with dupilumab with international experts in the field. #dermatology #globalcollaboration #Type2inflammation #atopicdermatitis #prurigonodularis

Webcast Alert! Chronic Spontaneous Urticaria: A Targeted Approach. Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both; it may be considered chronic if the symptoms persist for more than 6 weeks. In some patients, chronic urticaria will be spontaneous, meaning that triggers (whether known or unknown) inconsistently cause symptoms. Though relatively rare, chronic spontaneous urticaria (CSU) can be a debilitating, difficult-to-treat condition, hugely impacting patients’ quality of life in all domains. In order to direct patients with CSU to effective management regimens, clinicians first need to be confident in their ability to diagnose CSU. In this webcast, Brian S. Kim, MD, describes the pathophysiology of CSU, before delving into case examples and clinical trial evidence that support strategies for CSU management. Click here to start the webcast: https://bit.ly/3zCsHNV #Webcast #NACE #Dermatology